23 August 2024 - Lupin today announced that it has received approval from Health Canada for its biosimilar Pegfilgrastim. 

This product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech facility at Pune, India.

Read Lupin Pharmaceuticals press release